Literature DB >> 6643331

International collaborative study on standardization of bacterial sensitivity to fosfomycin.

J M Andrews, F Baquero, J M Beltran, E Canton, F Crokaert, M Gobernado, R Gomez-Ius, E Loza, M Navarro, T Olay.   

Abstract

An international collaborative study was undertaken involving 6 working groups to correlate the zone sizes obtained with 50 micrograms fosfomycin + 25 micrograms glucose-6-micrograms glucose-6-phosphate (G6P) and 50 micrograms fosfomycin + 50 micrograms G6P/disc with the MICs in the presence of 25 mg G6P/litre. The recommendations of the ICS for the MIC and disc diffusion methods were followed and Oxoid Mueller-Hinton agar was used. The regression lines obtained with the method of least squares show that the best correlation coefficient (r = 0.8227) corresponds to the disc with 50 micrograms fosfomycin + 50 micrograms G6P. Considering both the pharmacokinetics of fosfomycin after intravenous administration of 2 or 4 g and the distribution of sensitive bacterial populations, two breakpoints were established at MIC values of 16 and 64 mg/l corresponding to zone sizes and 18 and 22 mm, respectively.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6643331     DOI: 10.1093/jac/12.4.357

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  Susceptibility testing quality control studies with fosfomycin tromethamine.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

5.  In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia.

Authors:  W Y Lau; C H Teoh-Chan; S T Fan; K F Lau
Journal:  J Hyg (Lond)       Date:  1986-06

6.  Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

7.  Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.

Authors:  Wolfgang Poeppl; Tilman Lingscheid; Dominik Bernitzky; Uwe Y Schwarze; Oliver Donath; Thomas Perkmann; Nicolas Kozakowski; Roberto Plasenzotti; Gottfried Reznicek; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

8.  Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis.

Authors:  D Greenwood
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

9.  In vitro susceptibility testing procedures for fosfomycin tromethamine.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  In vitro activity of fludalanine combined with pentizidone compared with those of other agents.

Authors:  R Wise; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.